Skip to main
DMAC
DMAC logo

DMAC Stock Forecast & Price Target

DMAC Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DiaMedica Therapeutics Inc. is positioned for significant revenue growth, with probability-adjusted projections indicating revenues from its lead product candidate DM199 could escalate from $11.1 million in 2027 to $212.4 million by 2036, driven by its applications in acute ischemic stroke and preeclampsia. The company's ongoing Phase 2 clinical programs are bolstered by successful early-stage results, which may highlight the safety and efficacy of DM199, reducing risks associated with ischemic stroke treatments. Additionally, enhancements in the manufacturing process for DM199 support scalable production, aligning with the promising outcomes anticipated from its clinical trials and potential market expansion.

Bears say

DiaMedica Therapeutics has reported a net loss of $6.1 million or $0.15 per diluted share for the third quarter of 2024, indicating significant financial strains. There are considerable risks associated with its developmental candidates DM199 and DM300, including the potential failure to achieve projected peak commercial revenues due to market dynamics and the ability to secure necessary capital resources for ongoing operations. Furthermore, challenges in protecting intellectual property may hinder the company's competitive position in the biopharmaceutical sector, exacerbating concerns about its long-term viability.

DMAC has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DiaMedica Therapeutics Inc (DMAC) Forecast

Analysts have given DMAC a Strong Buy based on their latest research and market trends.

According to 6 analysts, DMAC has a Strong Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DiaMedica Therapeutics Inc (DMAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.